Xoft, Inc. announced that Medical Devices Bureau of Health Canada has granted a medical device license to sell and market the Axxent Electronic Brachytherapy System. The proprietary Electronic Brachytherapy (eBx) treatment platform is designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings under the supervision of a radiation oncologist to help reduce recurrence of cancer and improve survival. The Axxent system is commercially available in US since 2006 for treatment of early stage breast cancer, endometrial cancer, and skin and surface indications. The device is also cleared by the US FDA for use in the treatment of surface cancers or conditions where radiation therapy is indicated. The Axxent System as a cancer treatment platform addresses a variety of oncological and non-oncological indications. This system delivers non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. The Axxent system is intended to deliver electronic, X-ray-based radiation treatment and can be used in many clinical settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety. With the use of Axxent eBx System, physicians target cancer effectively and expands the ability to provide radiation therapy in remote locations. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.